Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer
NCT ID: NCT07230080
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
17 participants
OBSERVATIONAL
2024-09-01
2025-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a single-center, single-arm, retrospective study. All participants included in the analysis will have received the combined treatment regimen.
The main question the study aims to answer is:
Can sequential TACE-SBRT combined with targeted immunotherapy improve the objective response rate (ORR) in patients with intermediate to advanced HCC?
Interventions
Participants in this study have undergone the following treatments:
TACE: a minimally invasive procedure to block the blood supply to the tumor while delivering chemotherapy directly.
SBRT: a highly precise form of radiation therapy targeting the liver tumor. Targeted immunotherapy: systemic treatment that stimulates the immune system to recognize and attack cancer cells.
Participant Population The study includes adult patients diagnosed with intermediate to advanced HCC who were not candidates for curative resection or transplantation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
NCT05220020
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)
NCT03851887
A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC
NCT03116984
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
NCT04988945
The Efficacy of Sequential RT After Triple Therapy for uHCC
NCT07052448
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequential TACE-SBRT With Targeted Immunotherapy Group
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Unresectable hepatocellular carcinoma (HCC)
* CNLC stage IIb-IIIb
* Target lesion(s) not previously treated with local therapy
* Child-Pugh class A5-B7 liver function
* Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2
* At least one measurable lesion based on modified RECIST (mRECIST) criteria
Exclusion Criteria
* Currently participating in another interventional clinical study
* History of allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
* Presence of any severe or uncontrolled systemic disease
* Any medical history, comorbid condition, treatment, or abnormal laboratory finding that may interfere with study results or hinder full participation, or any other situation that the investigator considers inappropriate for enrollment
* Investigator's judgment of other potential risks making the patient unsuitable for participation in this study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanfang Hospital, Southern Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanfang Hosptial
Guangzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NFEC-2025-159
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.